AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17761229 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet Quality Index-Revised (DQI-R) intervention
Number of subjects: 182
Study 17761229 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 182
Study 15514264 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA Diet
Number of subjects: 23
Study 15514264 — intervention group
Group type: EXPERIMENTAL
Intervention: LA Diet
Number of subjects: 23
Study 15514264 — intervention group
Group type: COMPARATOR
Intervention: Both high-PUFA diets
Number of subjects: 23
Study 11344204 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning hypoglycemia (2.9 +/‐ 0.1 mmol/L)
Number of subjects: 24
Study 11344204 — intervention group
Group type: COMPARATOR
Intervention: Euglycemic control (5.1 +/‐ 0.1 mmol/L)
Number of subjects: 24
Study 10686414 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual double-step perturbation
Number of subjects: 0
Study 10686414 — intervention group
Group type: COMPARATOR
Intervention: Same spatial goal with different likelihood of visual double-step
Number of subjects: 0
Study 10437184 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage with relaxation
Number of subjects: 0
Study 10437184 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 10437184 — intervention group
Group type: COMPARATOR
Intervention: Control (no change in prescribed medication)
Number of subjects: 0
Study 1440172 — intervention group
Group type: COMPARATOR
Intervention: One axillary drain
Number of subjects: 84
Study 1440172 — intervention group
Group type: EXPERIMENTAL
Intervention: Two drains (one in axilla, one beneath pectoral flaps)
Number of subjects: 84
Study 1440172 — intervention group
Group type: EXPERIMENTAL
Intervention: Two drains
Number of subjects: 84
Study 2580866 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (600 mg tid)
Number of subjects: 14
Study 2580866 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (80 mg tid)
Number of subjects: 14
Study 31020598 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary antithrombotic stewardship
Number of subjects: 1886
Study 31020598 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosing of low-molecular-weight heparins (LMWHs)
Number of subjects: 1886
Study 30051166 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 575
Study 30051166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 575
Study 27712015 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab plus FOLFIRI
Number of subjects: 117
Study 27712015 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab plus FOLFIRI
Number of subjects: 117
Study 24891327 — intervention group
Group type: EXPERIMENTAL
Intervention: LVR coil treatment
Number of subjects: 60
Study 22955098 — intervention group
Group type: EXPERIMENTAL
Intervention: Information booklet with brief motivational interview
Number of subjects: 60
Study 22955098 — intervention group
Group type: EXPERIMENTAL
Intervention: Information booklet only
Number of subjects: 60
Study 22955098 — intervention group
Group type: COMPARATOR
Intervention: Informal discussion (control group)
Number of subjects: 60
Study 20650046 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion 0.2 microg/kg/min (G1)
Number of subjects: 30
Study 20650046 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion 0.2 microg/kg/min and low doses of ketamine infusion 1 microg/kg/min (G2)
Number of subjects: 30
Study 18614998 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART (highly active antiretroviral therapy)
Number of subjects: 508
Study 15834326 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine and methylprednisolone
Number of subjects: 86
Study 15834326 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine only
Number of subjects: 86
Study 11818344 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 37)
Number of subjects: 96
Study 11818344 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 42)
Number of subjects: 96
Study 11818344 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 96
Study 9920222 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed reminders during the immunization season of 1995
Number of subjects: 10000
Study 9920222 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 10000
Study 8772222 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic natural pentasaccharide (NP) administered subcutaneously at doses from 1.43 to 22.9 mg (1000 to 16,000 anti‐Xa IU)
Number of subjects: 20
Study 8772222 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic natural pentasaccharide (NP) administered at various dosages once or twice a day for 7 days
Number of subjects: 20
Study 8772222 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic natural pentasaccharide (NP) at highest dose regimens (single injection of 26.6 mg and repeated injections of 11.4 mg)
Number of subjects: 20
Study 2292115 — intervention group
Group type: EXPERIMENTAL
Intervention: TCM prescriptions of strengthening the patient's resistance and dispelling the invading evil in combination with chemotherapy
Number of subjects: 158
Study 2292115 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Chinese medicine with chemotherapy
Number of subjects: 158
Study 2292115 — intervention group
Group type: EXPERIMENTAL
Intervention: Decoction given to mice bearing Ehrlich ascites tumor
Number of subjects: 158
Study 30904947 — intervention group
Group type: COMPARATOR
Intervention: Control plots
Number of subjects: 0
Study 30904947 — intervention group
Group type: COMPARATOR
Intervention: Herbivore-exclusion plots
Number of subjects: 0
Study 30904947 — intervention group
Group type: EXPERIMENTAL
Intervention: Species sharing bees as pollinators
Number of subjects: 0
Study 30904947 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plot-level flowering time overlap
Number of subjects: 0
Study 30904947 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal niche differentiation
Number of subjects: 0
Study 28185625 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoiesis-Stimulating Agents (ESAs)
Number of subjects: 71
Study 28185625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 28185625 — intervention group
Group type: COMPARATOR
Intervention: Term healthy control
Number of subjects: 71
Study 26401735 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sugammadex (2 mg kg⁻¹)
Number of subjects: 38
Study 26401735 — intervention group
Group type: COMPARATOR
Intervention: No reversal agents (Control Group II)
Number of subjects: 38
Study 24098467 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin (2 mg/day)
Number of subjects: 225
Study 24098467 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 225
Study 24098467 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin (2 mg/day) in DM subgroup (n = 63)
Number of subjects: 225
Study 24098467 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (10 mg/day) in DM subgroup (n = 62)
Number of subjects: 225
Study 24098467 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 225
Study 21320950 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial chemotherapy (melphalan with or without topotecan)
Number of subjects: 78
Study 21320950 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial chemotherapy
Number of subjects: 78
Study 19158122 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral theophylline (100 mg twice daily)
Number of subjects: 35
Study 19158122 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (including systemic steroids)
Number of subjects: 35
Study 17338996 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (ROS)
Number of subjects: 86
Study 17338996 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 86
Study 14741300 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar patients
Number of subjects: 20
Study 14741300 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study 11455279 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultrafiltration (CUF)
Number of subjects: 41
Study 11455279 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional plus modified ultrafiltration (CUF+MUF)
Number of subjects: 41
Study 9586599 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 18000
Study 9586599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18000
Study 8061738 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody treatment for endotoxin-induced septic shock
Number of subjects: 0
Study 8061738 — intervention group
Group type: EXPERIMENTAL
Intervention: New techniques to supplement basic cardiopulmonary resuscitation
Number of subjects: 0
Study 8061738 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin treatment for respiratory syncytial virus infection in mechanically ventilated infants
Number of subjects: 0
Study 2969169 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 l O2/min
Number of subjects: 36
Study 2969169 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 l O2/min
Number of subjects: 36
Study 2969169 — intervention group
Group type: COMPARATOR
Intervention: No oxygen
Number of subjects: 36
Study 31729999 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate antiretroviral therapy (ART) starting within 7 days after initiation of opportunistic infection (OI) treatment
Number of subjects: 61
Study 31729999 — intervention group
Group type: COMPARATOR
Intervention: Deferred antiretroviral therapy (ART) starting after completing OI-therapy
Number of subjects: 61
Study 31729999 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ART
Number of subjects: 61
Study 31729999 — intervention group
Group type: COMPARATOR
Intervention: Deferred ART
Number of subjects: 61
Study 28248676 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% alcohol (single application in delivery room)
Number of subjects: 516
Study 28248676 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine (single application in delivery room)
Number of subjects: 516
Study 28248676 — intervention group
Group type: EXPERIMENTAL
Intervention: povidon-iodine (single application in delivery room)
Number of subjects: 516
Study 28248676 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% alcohol (application every six hours until discharge)
Number of subjects: 516
Study 28248676 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine (application every six hours until discharge)
Number of subjects: 516
Study 28248676 — intervention group
Group type: COMPARATOR
Intervention: dry care
Number of subjects: 516
Study 25319717 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation
Number of subjects: 0
Study 25319717 — intervention group
Group type: EXPERIMENTAL
Intervention: Perspective exercise
Number of subjects: 0
Study 25319717 — intervention group
Group type: COMPARATOR
Intervention: Standard self-affirmation manipulation
Number of subjects: 0
Study 23809455 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle (DB) ACL reconstruction
Number of subjects: 80
Study 23809455 — intervention group
Group type: COMPARATOR
Intervention: Single-bundle (SB) ACL reconstruction
Number of subjects: 80
Study 22204723 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg daily) plus elastic stockings with graduated compression
Number of subjects: 8307
Study 22204723 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus elastic stockings with graduated compression
Number of subjects: 8307
Study 18196200 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) treatment during TMS
Number of subjects: 21
Study 18196200 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 21
Study 16544582 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (R) 25mg
Number of subjects: 19
Study 16544582 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (ASA)
Number of subjects: 19
Study 12635916 — intervention group
Group type: EXPERIMENTAL
Intervention: Dominant confederate (postural expansion)
Number of subjects: 0
Study 12635916 — intervention group
Group type: EXPERIMENTAL
Intervention: Submissive confederate (postural constriction)
Number of subjects: 0
Study 12635916 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementarity (dominance in response to submission and submission in response to dominance)
Number of subjects: 0
Study 12635916 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementarity
Number of subjects: 0
Study 12635916 — intervention group
Group type: COMPARATOR
Intervention: Mimicry
Number of subjects: 0
Study 10711861 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral L-arginine (9 g daily for 1 month)
Number of subjects: 10
Study 10711861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9198053 — intervention group
Group type: EXPERIMENTAL
Intervention: Na+ lactate
Number of subjects: 40
Study 9198053 — intervention group
Group type: COMPARATOR
Intervention: Na+ HCO3‐
Number of subjects: 40
Study 1534048 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 278
Study 1534048 — intervention group
Group type: COMPARATOR
Intervention: Conventional cholecystectomy
Number of subjects: 278
Study 3899317 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg
Number of subjects: 132
Study 3899317 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 132
Study 3899317 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients (Control)
Number of subjects: 132
Study 3899317 — intervention group
Group type: EXPERIMENTAL
Intervention: Premedicated patients (within 75-200 minutes of surgery)
Number of subjects: 132
Study 29793929 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed incentive (£10 cash for attending screening)
Number of subjects: 1051
Study 29793929 — intervention group
Group type: EXPERIMENTAL
Intervention: Lottery incentive (1 in 100 chance of winning £1000)
Number of subjects: 1051
Study 29793929 — intervention group
Group type: COMPARATOR
Intervention: Control (usual invitation letter)
Number of subjects: 1051
Study 28802103 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor alignment (participants' to-be-imagined orientation aligned with physical orientation)
Number of subjects: 0
Study 28802103 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor misalignment (participants' to-be-imagined orientation misaligned with physical orientation)
Number of subjects: 0
Study 28802103 — intervention group
Group type: EXPERIMENTAL
Intervention: Similar geometry between learning and test environments
Number of subjects: 0
Study 28802103 — intervention group
Group type: EXPERIMENTAL
Intervention: Different geometry between learning and test environments
Number of subjects: 0
Study 25601322 — intervention group
Group type: EXPERIMENTAL
Intervention: Spermatozoa treated with myoinositol
Number of subjects: 500
Study 25601322 — intervention group
Group type: COMPARATOR
Intervention: Spermatozoa treated with placebo
Number of subjects: 500
Study 24021033 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-setting intervention during asthma review consultation
Number of subjects: 80
Study 24021033 — intervention group
Group type: COMPARATOR
Intervention: Usual care guideline-based review of asthma
Number of subjects: 80
Study 24021033 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-setting intervention
Number of subjects: 80
Study 21226939 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated therapeutic hypothermia (32-35 °C) with intravenous 0.9% saline (20-30 ml/kg) and maintained for at least 48 hours or longer as needed to keep intracranial pressure <20 mmHg.
Number of subjects: 1800
Study 21226939 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 1800
Study 18653816 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Discharge Plan (MDP)
Number of subjects: 83
Study 18653816 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 83
Study 16863712 — intervention group
Group type: EXPERIMENTAL
Intervention: EC-high-buffered pancrelipase
Number of subjects: 18
Study 16863712 — intervention group
Group type: COMPARATOR
Intervention: EC-nonbuffered enzymes
Number of subjects: 18
Study 15648730 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequence condition (repeating sequence of three problems)
Number of subjects: 36
Study 15648730 — intervention group
Group type: COMPARATOR
Intervention: Random condition (nonrecurring problems)
Number of subjects: 36
Study 11410720 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (4 microg/kg twice a day) and naltrexone (25 mg twice a day)
Number of subjects: 20
Study 11410720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9248764 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol 1 microgram per day for 5 consecutive days
Number of subjects: 59
Study 9248764 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (PZQ) 60 mg.kg-1 on day 1 plus calcitriol 1 microgram per day orally for 5 consecutive days
Number of subjects: 59
Study 9248764 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (PZQ) 60 mg.kg-1 on day 1
Number of subjects: 59
Study 9248764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 8363113 — intervention group
Group type: COMPARATOR
Intervention: N‐acetylcysteine (140 mg/kg)
Number of subjects: 10
Study 8363113 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (60 g) + N‐acetylcysteine (235 mg/kg)
Number of subjects: 10
Study 3306781 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol (nonionic agent)
Number of subjects: 54
Study 3306781 — intervention group
Group type: COMPARATOR
Intervention: Iothalamate meglumine (ionic agent)
Number of subjects: 54
Study 31738378 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-testing (ST) group received 4 HIV self-tests and access to online resources and counseling.
Number of subjects: 2665
Study 31738378 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-testing (ST) group
Number of subjects: 2665
Study 31738378 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2665
Study 30107239 — intervention group
Group type: EXPERIMENTAL
Intervention: RHO guided oxygen weaning
Number of subjects: 196
Study 30107239 — intervention group
Group type: COMPARATOR
Intervention: Standard home oxygen therapy management
Number of subjects: 196
Study 26429200 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day
Number of subjects: 0
Study 26429200 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day with ubiquinol supplementation
Number of subjects: 0
Study 26429200 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 25265769 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal hyperbaric bupivacaine 10 mg plus fentanyl 10 g
Number of subjects: 90
Study 25265769 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal bupivacaine 11 mg plus fentanyl 10 g
Number of subjects: 90
Study 25265769 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal levobupivacaine 11 mg plus fentanyl 10 g
Number of subjects: 90
Study 22430286 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with drug-eluting stent
Number of subjects: 0
Study 22430286 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass surgery (CABG)
Number of subjects: 0
Study 20404738 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 0
Study 20404738 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 0
Study 18779612 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg/d orally)
Number of subjects: 196
Study 18779612 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine (30 mg/m2 infusion on days 1 and 8 of a 21-day cycle)
Number of subjects: 196
Study 18779612 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR FISH-positive patients
Number of subjects: 196
Study 15929952 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (30 mg q.d. for 2 weeks)
Number of subjects: 0
Study 15929952 — intervention group
Group type: EXPERIMENTAL
Intervention: Refractory asthma
Number of subjects: 0
Study 15929952 — intervention group
Group type: COMPARATOR
Intervention: Mild-to-moderate asthma
Number of subjects: 0
Study 15929952 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study 11217593 — intervention group
Group type: EXPERIMENTAL
Intervention: Z100 (3M Dental Products)
Number of subjects: 38
Study 11217593 — intervention group
Group type: EXPERIMENTAL
Intervention: Prisma TPH (Caulk/Dentsply)
Number of subjects: 38
Study 11217593 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Ray‐Posterior (Kuraray Co. Ltd.)
Number of subjects: 38
Study 11217593 — intervention group
Group type: COMPARATOR
Intervention: All materials
Number of subjects: 38
Study 8955997 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,100 ppm fluoride dentifrice
Number of subjects: 30
Study 8955997 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 ppm fluoride dentifrice
Number of subjects: 30
Study 8955997 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 30
Study 7837145 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with SLE
Number of subjects: 70
Study 7837145 — intervention group
Group type: COMPARATOR
Intervention: Patients with RA
Number of subjects: 70
Study 7837145 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 70
Study 3131470 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous desmopressin acetate (0.4 microgram/kg)
Number of subjects: 9
Study 3131470 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal drops and intranasal spray of desmopressin acetate
Number of subjects: 9
Study 3131470 — intervention group
Group type: COMPARATOR
Intervention: Venous occlusion test
Number of subjects: 9
Study 3131470 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous desmopressin acetate
Number of subjects: 9
Study 3131470 — intervention group
Group type: COMPARATOR
Intervention: Euglobulin lysis time, t-PA activity, t-PA antigen levels, and t-PA fast-acting inhibitor (PAI) level
Number of subjects: 9